Explore

Trendline Trendline
Arrowhead Pharmaceuticals Reports Strong Growth and New Developments in RNAi Therapeutics

Arrowhead Pharmaceuticals Reports Strong Growth and New Developments in RNAi Therapeutics

Arrowhead Pharmaceuticals Reports Strong Growth and New Developments in RNAi Therapeutics
Trendline Trendline
Nektar Therapeutics Strengthens Financial Position Amidst Development of Lead Biologic Candidate

Nektar Therapeutics Strengthens Financial Position Amidst Development of Lead Biologic Candidate

Nektar Therapeutics Strengthens Financial Position Amidst Development of Lead Biologic Candidate
Trendline Trendline
Rocket Pharmaceuticals Reports Financial Results and Advances Gene Therapy Pipeline

Rocket Pharmaceuticals Reports Financial Results and Advances Gene Therapy Pipeline

Rocket Pharmaceuticals Reports Financial Results and Advances Gene Therapy Pipeline
Trendline Trendline
Sarepta Therapeutics Reports Q1 2026 Financial Results Amidst Strategic Developments

Sarepta Therapeutics Reports Q1 2026 Financial Results Amidst Strategic Developments

Sarepta Therapeutics Reports Q1 2026 Financial Results Amidst Strategic Developments
Trendline Trendline
Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead

Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead

Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead
Trendline Trendline
Arrowhead Pharmaceuticals Licenses RNAi Therapeutic for MASH to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses RNAi Therapeutic for MASH to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses RNAi Therapeutic for MASH to Madrigal Pharmaceuticals
Trendline Trendline
Madrigal Pharmaceuticals Expands siRNA Portfolio with $1B Arrowhead Deal

Madrigal Pharmaceuticals Expands siRNA Portfolio with $1B Arrowhead Deal

Madrigal Pharmaceuticals Expands siRNA Portfolio with $1B Arrowhead Deal
Trendline Trendline
Madrigal Pharmaceuticals Expands siRNA Pipeline with $1 Billion Deal for MASH Treatment

Madrigal Pharmaceuticals Expands siRNA Pipeline with $1 Billion Deal for MASH Treatment

Madrigal Pharmaceuticals Expands siRNA Pipeline with $1 Billion Deal for MASH Treatment
Trendline Trendline
Arrowhead Pharmaceuticals Licenses MASH Program to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses MASH Program to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses MASH Program to Madrigal Pharmaceuticals
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026